TapewireFind a company

person · Reporting owner

Scanlan Jacqueline

Disclosed activity across 3 companies

Tapewire entity
64871
SEC CIK
0001713517

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Axalta Coating Systems Ltd.AXTA · Entity 3667SVP & CHROAugust 09, 2023August 11, 2023
FMC CORPFMC · Entity 4704Executive VP & Chief HROSeptember 28, 2026September 30, 2026
HAEMONETICS CORPHAE · Entity 3953SVP, Global Human ResourcesJune 07, 2021June 09, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Axalta Coating Systems Ltd.

Report date August 09, 2023 · Filed August 11, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect4,001 Reported balance After 2023-08-09 transaction · row 1
1 source row

Row 1 · 2023-08-09 · Sale · Disposed 17,008 · Balance 4,001

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.47 to $29.51. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.47 to $29.51. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

FMC CORP

Report date September 28, 2026 · Filed September 30, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect63,558 Reported balance After 2026-09-28 transaction · row 1
1 source row

Row 1 · 2026-09-28 · Tax withholding · Disposed 5,137 · Balance 63,558

HAEMONETICS CORP

Report date June 07, 2021 · Filed June 09, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect4,216 Reported balance After 2021-06-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2021-06-07 · Sale · Disposed 195 · Balance 4,216

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: This number includes unvested RSUs previously reported.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: This number includes unvested RSUs previously reported.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 28, 2026 Filed Sep 30, 2026 20:19 UTC FMC CORP FMC · Entity 4704 Tax withholdingCommon Stock 5,137 $9.58 $49,212.46
Disclosure

SEC source: 0000037785-26-000146 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,558

Read SEC document
February 23, 2026 Filed Feb 26, 2026 00:50 UTC FMC CORP FMC · Entity 4704 Tax withholdingCommon Stock 1,404 $14.62 $20,526.48
Disclosure

SEC source: 0000950103-26-002678 · dp242146_4-scanlan.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,695

Read SEC document
February 19, 2026 Filed Feb 24, 2026 01:30 UTC FMC CORP FMC · Entity 4704 GrantCommon Stock 42,232 $0.00 $0.00
Disclosure

SEC source: 0000950103-26-002511 · dp241974_4-scanlan.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,099

Read SEC document
September 29, 2025 Filed Sep 30, 2025 17:09 UTC FMC CORP FMC · Entity 4704 Tax withholdingCommon Stock 5,177 $33.64 $174,154.28
Disclosure

SEC source: 0000037785-25-000088 · form4.xml · nonDerivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,867

Read SEC document
September 29, 2025 Filed Sep 30, 2025 17:09 UTC FMC CORP FMC · Entity 4704 SaleCommon Stock 3,790 $34.00 $128,860.00
Disclosure

SEC source: 0000037785-25-000088 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,044

F1 · ownership.direct: The reported sale of 3,790 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2025.

Read SEC document
August 18, 2025 Filed Aug 19, 2025 18:21 UTC FMC CORP FMC · Entity 4704 SaleCommon Stock 1,510 $37.49 $56,609.90
Disclosure

SEC source: 0000037785-25-000085 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,834

Read SEC document
February 21, 2025 Filed Feb 25, 2025 17:55 UTC FMC CORP FMC · Entity 4704 GrantStock Option (Right to Buy) · Derivative 44,808 $0.00 Strike: $38.25 $0.00
Disclosure

SEC source: 0001127602-25-006516 · form4.xml · derivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,808

Underlying: Common Stock · 44,808 shares

Expires 2035-02-21

Read SEC document
February 21, 2025 Filed Feb 25, 2025 17:55 UTC FMC CORP FMC · Entity 4704 GrantCommon Stock 9,084 $0.00 $0.00
Disclosure

SEC source: 0001127602-25-006516 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,344

Read SEC document
February 18, 2025 Filed Feb 21, 2025 01:25 UTC FMC CORP FMC · Entity 4704 GrantCommon Stock 28 $0.00 $0.00
Disclosure

SEC source: 0001127602-25-006105 · form4.xml · nonDerivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,260

Read SEC document
February 18, 2025 Filed Feb 21, 2025 01:25 UTC FMC CORP FMC · Entity 4704 GrantCommon Stock 583 $0.00 $0.00
Disclosure

SEC source: 0001127602-25-006105 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,232

Read SEC document
November 11, 2024 Filed Nov 13, 2024 18:47 UTC FMC CORP FMC · Entity 4704 SaleCommon Stock 4,529 $59.67 $270,245.43
Disclosure

SEC source: 0001127602-24-027176 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,649

Read SEC document
September 27, 2024 Filed Oct 1, 2024 12:34 UTC FMC CORP FMC · Entity 4704 Tax withholdingCommon Stock 5,132 $65.97 $338,558.04
Disclosure

SEC source: 0001127602-24-024581 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,178

Read SEC document
February 20, 2024 Filed Feb 22, 2024 20:19 UTC FMC CORP FMC · Entity 4704 GrantStock Option (Right to Buy) · Derivative 19,167 $50.99 Strike: $50.99 $977,325.33
Disclosure

SEC source: 0001127602-24-006254 · form4.xml · derivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,167

Underlying: Common Stock · 19,167 shares

Expires 2034-02-20

Read SEC document
February 20, 2024 Filed Feb 22, 2024 20:19 UTC FMC CORP FMC · Entity 4704 GrantCommon Stock 4,799 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-006254 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,310

Read SEC document
September 27, 2023 Filed Sep 29, 2023 14:29 UTC FMC CORP FMC · Entity 4704 GrantCommon Stock 33,511 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-024846 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,511

F1 · shares: Represents a grant of 33,511 restricted stock units ("RSUs"). The RSUs vest in three annual installments on the first, second, and third anniversaries of the grant date contingent on the reporting person's continued service on each applicable vesting date, subject to accelerated vesting under certain circumstances.

Read SEC document
August 09, 2023 Filed Aug 11, 2023 20:30 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 SaleCommon Shares 17,008 $29.48 $501,395.84
Disclosure

SEC source: 0001209191-23-045443 · doc4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,001

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.47 to $29.51. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 27, 2023 Filed Jul 28, 2023 21:51 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Exercise / conversionRestricted Stock Units · Derivative 16,266 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043717 · doc4.xml · derivative · entry 3

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,267

Underlying: Common Shares · 16,266 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common shares on a one-for-one basis.

F3 · derivative.exercise_date: On July 27, 2022, the reporting person was granted 32,533 restricted stock units, vesting in two equal annual installments on the first and second anniversaries of the grant date.

F3 · derivative.expiration_date: On July 27, 2022, the reporting person was granted 32,533 restricted stock units, vesting in two equal annual installments on the first and second anniversaries of the grant date.

Read SEC document
July 27, 2023 Filed Jul 28, 2023 21:51 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Tax withholdingCommon Shares 6,910 $32.03 $221,327.30
Disclosure

SEC source: 0001209191-23-043717 · doc4.xml · nonDerivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,009

F2 · shares: Shares withheld to satisfy the tax withholding obligation applicable to the vesting of a portion of a restricted stock unit award.

Read SEC document
July 27, 2023 Filed Jul 28, 2023 21:51 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Exercise / conversionCommon Shares 16,266 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-043717 · doc4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,919

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common shares on a one-for-one basis.

Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:05 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Exercise / conversionRestricted Stock Units · Derivative 11,545 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-037971 · doc4.xml · derivative · entry 6

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,545

Underlying: Common Shares · 11,545 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common shares on a one-for-one basis.

F4 · derivative.exercise_date: On June 14, 2021, the reporting person was granted 23,090 restricted stock units, vesting 50% on each of the second and third anniversaries of the grant date.

F4 · derivative.expiration_date: On June 14, 2021, the reporting person was granted 23,090 restricted stock units, vesting 50% on each of the second and third anniversaries of the grant date.

Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:05 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Exercise / conversionRestricted Stock Units · Derivative 2,873 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-037971 · doc4.xml · derivative · entry 5

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,874

Underlying: Common Shares · 2,873 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common shares on a one-for-one basis.

F3 · derivative.exercise_date: On June 14, 2021, the reporting person was granted 8,620 restricted stock units, vesting in three equal annual installments beginning on June 14, 2022.

F3 · derivative.expiration_date: On June 14, 2021, the reporting person was granted 8,620 restricted stock units, vesting in three equal annual installments beginning on June 14, 2022.

Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:05 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Tax withholdingCommon Shares 4,905 $32.50 $159,412.50
Disclosure

SEC source: 0001209191-23-037971 · doc4.xml · nonDerivative · entry 4

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,653

F2 · shares: Shares withheld to satisfy the tax withholding obligation applicable to the vesting of a portion of a restricted stock unit award.

Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:05 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Exercise / conversionCommon Shares 11,545 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-037971 · doc4.xml · nonDerivative · entry 3

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common shares on a one-for-one basis.

Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:05 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Tax withholdingCommon Shares 1,221 $32.50 $39,682.50
Disclosure

SEC source: 0001209191-23-037971 · doc4.xml · nonDerivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,013

F2 · shares: Shares withheld to satisfy the tax withholding obligation applicable to the vesting of a portion of a restricted stock unit award.

Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:05 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Exercise / conversionCommon Shares 2,873 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-037971 · doc4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common shares on a one-for-one basis.

Read SEC document
February 28, 2023 Filed Mar 3, 2023 01:23 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 GrantRestricted Stock Units · Derivative 10,739 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-015028 · doc4.xml · derivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,739

Underlying: Common Shares · 10,739 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Axalta Coating Systems Ltd.

F2 · derivative.exercise_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date.

F2 · derivative.expiration_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
February 15, 2023 Filed Feb 17, 2023 22:39 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Exercise / conversionRestricted Stock Units · Derivative 3,238 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-010829 · doc4.xml · derivative · entry 3

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,478

Underlying: Common Shares · 3,238 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common shares on a one-for-one basis.

F3 · derivative.exercise_date: On February 15, 2022, the reporting person was granted 9,716 restricted stock units, vesting in three equal annual installments beginning on February 15, 2023.

F3 · derivative.expiration_date: On February 15, 2022, the reporting person was granted 9,716 restricted stock units, vesting in three equal annual installments beginning on February 15, 2023.

Read SEC document
February 15, 2023 Filed Feb 17, 2023 22:39 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Tax withholdingCommon Shares 1,529 $29.55 $45,181.95
Disclosure

SEC source: 0001209191-23-010829 · doc4.xml · nonDerivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,361

F2 · shares: Shares withheld to satisfy the tax withholding obligation applicable to the vesting of a portion of a restricted stock unit award.

Read SEC document
February 15, 2023 Filed Feb 17, 2023 22:39 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Exercise / conversionCommon Shares 3,238 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-010829 · doc4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,890

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common shares on a one-for-one basis.

Read SEC document
July 27, 2022 Filed Jul 27, 2022 22:59 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 GrantRestricted Stock Units · Derivative 32,533 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-043310 · doc4.xml · derivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,533

Underlying: Common Shares · 32,533 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Axalta Coating Systems Ltd.

F2 · derivative.exercise_date: This restricted stock unit grant vests in two equal annual installments on the first and second anniversaries of the grant date.

F2 · derivative.expiration_date: This restricted stock unit grant vests in two equal annual installments on the first and second anniversaries of the grant date.

Read SEC document
June 14, 2022 Filed Jun 16, 2022 21:34 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Exercise / conversionRestricted Stock Units · Derivative 2,873 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-037534 · doc4.xml · derivative · entry 3

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,747

Underlying: Common Shares · 2,873 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common shares on a one-for-one basis.

F3 · derivative.exercise_date: On June 14, 2021, the reporting person was granted 8,620 restricted stock units, vesting in three equal annual installments beginning on June 14, 2022.

F3 · derivative.expiration_date: On June 14, 2021, the reporting person was granted 8,620 restricted stock units, vesting in three equal annual installments beginning on June 14, 2022.

Read SEC document
June 14, 2022 Filed Jun 16, 2022 21:34 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Tax withholdingCommon Shares 1,221 $24.20 $29,548.20
Disclosure

SEC source: 0001209191-22-037534 · doc4.xml · nonDerivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,652

F2 · shares: Shares withheld to satisfy the tax withholding obligation applicable to the vesting of a portion of a restricted stock unit award.

Read SEC document
June 14, 2022 Filed Jun 16, 2022 21:34 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 Exercise / conversionCommon Shares 2,873 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-037534 · doc4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,873

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common shares on a one-for-one basis.

Read SEC document
February 15, 2022 Filed Feb 18, 2022 00:00 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 GrantRestricted Stock Units · Derivative 9,716 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-011020 · doc4.xml · derivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,716

Underlying: Common Shares · 9,716 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Axalta Coating Systems Ltd.

F2 · derivative.exercise_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date.

F2 · derivative.expiration_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
June 14, 2021 Filed Jun 16, 2021 21:39 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 GrantRestricted Stock Units · Derivative 8,620 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-041020 · doc4.xml · derivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,620

Underlying: Common Shares · 8,620 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Axalta Coating Systems Ltd.

F3 · derivative.exercise_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date.

F3 · derivative.expiration_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
June 14, 2021 Filed Jun 16, 2021 21:39 UTC Axalta Coating Systems Ltd. AXTA · Entity 3667 GrantRestricted Stock Units · Derivative 23,090 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-041020 · doc4.xml · derivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,090

Underlying: Common Shares · 23,090 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Axalta Coating Systems Ltd.

F2 · derivative.exercise_date: This restricted stock unit grant vests 50% on each of the second and third anniversaries of the grant date.

F2 · derivative.expiration_date: This restricted stock unit grant vests 50% on each of the second and third anniversaries of the grant date.

Read SEC document
June 07, 2021 Filed Jun 9, 2021 20:33 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 195 $55.09 $10,742.55
Disclosure

SEC source: 0001127602-21-019526 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,216

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 19, 2021 Filed May 21, 2021 10:26 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 112 $55.19 $6,181.28
Disclosure

SEC source: 0001127602-21-017698 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,411

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 17, 2021 Filed May 18, 2021 22:27 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 102 $55.97 $5,708.94
Disclosure

SEC source: 0001127602-21-017269 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,523

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021.

Read SEC document
March 08, 2021 Filed Mar 10, 2021 21:11 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 107 $120.07 $12,847.49
Disclosure

SEC source: 0001127602-21-010074 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,380

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
June 16, 2020 Filed Jun 16, 2020 21:53 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 6,869 $91.53 $628,719.57
Disclosure

SEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 6

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,487

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
June 15, 2020 Filed Jun 16, 2020 21:53 UTC HAEMONETICS CORP HAE · Entity 3953 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 2,889 $0.00 Strike: $41.64 $0.00
Disclosure

SEC source: 0001127602-20-019788 · form4.xml · derivative · entry 7

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,890

Underlying: Common Stock · 2,889 shares

Expires 2024-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
June 15, 2020 Filed Jun 16, 2020 21:53 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 4,005 $90.00 $360,450.00
Disclosure

SEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 5

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,356

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
June 15, 2020 Filed Jun 16, 2020 21:53 UTC HAEMONETICS CORP HAE · Entity 3953 Exercise / conversionCommon Stock 2,889 $41.64 $120,297.96
Disclosure

SEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 4

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,361

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
June 15, 2020 Filed Jun 16, 2020 21:53 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 4,417 $87.71 $387,415.07
Disclosure

SEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 3

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,472

F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
June 12, 2020 Filed Jun 16, 2020 21:53 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 111 $89.29 $9,911.19
Disclosure

SEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,889

F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
June 12, 2020 Filed Jun 16, 2020 21:53 UTC HAEMONETICS CORP HAE · Entity 3953 GrantCommon Stock 11,286 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

F1 · kind: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020.

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
June 08, 2020 Filed Jun 10, 2020 21:59 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 324 $97.03 $31,437.72
Disclosure

SEC source: 0001127602-20-019381 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,714

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 18, 2020 Filed May 19, 2020 21:34 UTC HAEMONETICS CORP HAE · Entity 3953 GrantNon-qualified Stock Option (Right to Buy) · Derivative 5,319 $0.00 Strike: $103.37 $0.00
Disclosure

SEC source: 0001127602-20-017266 · form4.xml · derivative · entry 3

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,319

Underlying: Common Stock · 5,319 shares

Expires 2027-05-18

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
May 18, 2020 Filed May 19, 2020 21:34 UTC HAEMONETICS CORP HAE · Entity 3953 GrantCommon Stock 1,572 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-20-017266 · form4.xml · nonDerivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,038

F3 · kind: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs and 193 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2020.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.